EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gain-of-function variants in the ion channel gene TRPM3 underlie a spectrum of neurodevelopmental disorders

Lydie Burglen, Evelien Van Hoeymissen iD, Leila Qebibo, Magalie Barth, Newell Belnap, Felix Boschann, Christel Depienne, Katrien De Clercq, Andrew G L Douglas, Mark P Fitzgerald, Nicola Foulds, Catherine Garel und 20 weitere

eLife · 17.01.2023 · 12

DOI: 10.7554/elife.81032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 17.01.2023. Verfasst von Lydie Burglen und 31 weiteren Autor:innen. Beteiligte Einrichtung: Centre de référence des malformations et maladies congénitales du cervelet, Départementde Génétique, APHP, Sorbonne University, Paris, France. Hauptthemen laut MEDLINE: Neurosteroids, Neurodevelopmental Disorders, Epilepsy, TRPM Cation Channels. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FWO, Queen Elisabeth Medical Foundation for Neurosciences, Vlaams Instituut voor Biotechnologie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TRPM3 is a temperature- and neurosteroid-sensitive plasma membrane cation channel expressed in a variety of neuronal and non-neuronal cells. Recently, rare de novo variants in TRPM3 were identified in individuals with developmental and epileptic encephalopathy, but the link between TRPM3 activity and neuronal disease remains poorly understood. We previously reported that two disease-associated variants in TRPM3 lead to a gain of channel function . Here, we report a further 10 patients carrying one of seven additional heterozygous TRPM3 missense variants. These patients present with a broad spectrum of neurodevelopmental symptoms, including global developmental delay, intellectual disability, epilepsy, musculo-skeletal anomalies, and altered pain perception. We describe a cerebellar phenotype with ataxia or severe hypotonia, nystagmus, and cerebellar atrophy in more than half of the patients. All disease-associated variants exhibited a robust gain-of-function phenotype, characterized by increased basal activity leading to cellular calcium overload and by enhanced responses to the neurosteroid ligand pregnenolone sulfate when co-expressed with wild-type TRPM3 in mammalian cells. The antiseizure medication primidone, a known TRPM3 antagonist, reduced the increased basal activity of all mutant channels. These findings establish gain-of-function of TRPM3 as the cause of a spectrum of autosomal dominant neurodevelopmental disorders with frequent cerebellar involvement in humans and provide support for the evaluation of TRPM3 antagonists as a potential therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurosteroidsNeurodevelopmental DisordersEpilepsyTRPM Cation ChannelsAnimalsHumansGain of Function MutationIon ChannelsMammals

Stichwörter der Autor:innen

TRPM3cell biologycerebellar atrophyepilepsygain-of-functionhumanintellectual disabilityneurodevelopmentneuroscience

Substanzen

NeurosteroidsIon ChannelsTRPM Cation ChannelsTRPM3 protein, human

Autor:innen und Institutionen

  • Centre de référence des malformations et maladies congénitales du cervelet, Départementde Génétique, APHP, Sorbonne University, Paris, France.
  • Developmental Brain Disorders Laboratory, Imagine Institute, Paris, France.
  • Laboratory of Ion Channel Research, Department of cellular and molecular medicine, University of Leuven, Leuven, Belgium.
  • VIB Center for Brain & Disease Research, Leuven, Belgium.
  • Laboratory of Endometrium, Endometriosis & Reproductive Medicine, Department Development & Regeneration, University of Leuven, Leuven, Belgium.
  • Department of Genetics, University Hospital of Angers, Angers, France.

ORCID-Profile: Evelien Van Hoeymissen, Denise Horn, Annelies Janssen, Angela M Kaindl, Vinodh Narayanan, Siyuan Zhao, Tibor Rohacs, Joris Vriens

Förderung

  • FWO
  • Queen Elisabeth Medical Foundation for Neurosciences
  • Vlaams Instituut voor Biotechnologie

Zitieren

APA

Burglen, L., Van Hoeymissen, E., Qebibo, L., Barth, M., Belnap, N., Boschann, F., Depienne, C., De Clercq, K., Douglas, A. G. L., Fitzgerald, M. P., Foulds, N., Garel, C., Helbig, I., Held, K., Horn, D., Janssen, A., Kaindl, A. M., Narayanan, V., Prager, C., …, & Vriens, J. (2023). Gain-of-function variants in the ion channel gene TRPM3 underlie a spectrum of neurodevelopmental disorders. eLife, 12. https://doi.org/10.7554/elife.81032

Vancouver

Burglen L, Van Hoeymissen E, Qebibo L, Barth M, Belnap N, Boschann F, et al. Gain-of-function variants in the ion channel gene TRPM3 underlie a spectrum of neurodevelopmental disorders. eLife. 2023;12. doi:10.7554/elife.81032

BibTeX
@article{Burglen2023,
  author = {Burglen, Lydie and Van Hoeymissen, Evelien and Qebibo, Leila and Barth, Magalie and Belnap, Newell and Boschann, Felix and Depienne, Christel and De Clercq, Katrien and Douglas, Andrew G L and Fitzgerald, Mark P and Foulds, Nicola and Garel, Catherine and Helbig, Ingo and Held, Katharina and Horn, Denise and Janssen, Annelies and Kaindl, Angela M and Narayanan, Vinodh and Prager, Christina and Rupin-Mas, Mailys and Afenjar, Alexandra and Zhao, Siyuan and Ramaekers, Vincent Th and Ruggiero, Sarah M and Thomas, Simon and Valence, Stéphanie and Van Maldergem, Lionel and Rohacs, Tibor and Rodriguez, Diana and Dyment, David and Voets, Thomas and Vriens, Joris},
  title = {Gain-of-function variants in the ion channel gene TRPM3 underlie a spectrum of neurodevelopmental disorders},
  journal = {eLife},
  year = {2023},
  volume = {12},
  doi = {10.7554/elife.81032}
}
Kostenlos starten →